<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nadroparin (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nadroparin (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nadroparin (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12037" href="/d/html/12037.html" rel="external">see "Nadroparin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867623"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fraxiparine;</li>
<li>Fraxiparine Forte</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F199059"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant;</li>
<li>
                        Anticoagulant, Low Molecular Weight Heparin</li></ul></div>
<div class="block doa drugH1Div" id="F199028"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome (unstable angina and non–ST-elevation myocardial infarction [non–Q-wave myocardial infarction]):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: <b>IV:</b> 86 anti-Xa units/kg one time bolus (maximum dose: 9,500 anti-Xa units).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">&lt;50 kg: 3,800 anti-Xa units one time bolus.</p>
<p style="text-indent:-2em;margin-left:8em;">50 to 59 kg: 4,750 anti-Xa units one time bolus.</p>
<p style="text-indent:-2em;margin-left:8em;">60 to 69 kg: 5,700 anti-Xa units one time bolus.</p>
<p style="text-indent:-2em;margin-left:8em;">70 to 79 kg: 6,650 anti-Xa units one time bolus.</p>
<p style="text-indent:-2em;margin-left:8em;">80 to 89 kg: 7,600 anti-Xa units one time bolus.</p>
<p style="text-indent:-2em;margin-left:8em;">90 to 99 kg: 8,550 anti-Xa units one time bolus.</p>
<p style="text-indent:-2em;margin-left:8em;">≥100 kg: 9,500 anti-Xa units one time bolus.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: <b>Note:</b> Begin 12 hours after initial bolus. Usual treatment duration: 6 days; plasma anti-Xa levels should be &lt;1.2 anti-Xa units/mL 3 to 4 hours postinjection.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: <b>SUBQ:</b> 86 anti-Xa units/kg every 12 hours (maximum total daily dose: 19,000 anti-Xa units/day).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: <b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:8em;">&lt;50 kg: 3,800 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">50 to 59 kg: 4,750 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">60 to 69 kg: 5,700 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">70 to 79 kg: 6,650 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">80 to 89 kg: 7,600 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">90 to 99 kg: 8,550 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">≥100 kg: 9,500 anti-Xa units every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e95a9db-43d6-42c1-8cc7-f4ef40a835b7">Deep vein thrombosis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For timing of initiating oral anticoagulant, see "<b>Transitioning Between Anticoagulants</b>."</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inpatient treatment: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients with standard bleeding risk:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-based dosing:<b> SUBQ: </b>171 anti-Xa units/kg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Fixed dosing: <b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:10em;">40 to 49 kg: 7,600 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">50 to 59 kg: 9,500 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">60 to 69 kg: 11,400 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">70 to 79 kg: 13,300 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">80 to 89 kg: 15,200 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">≥90 kg: 17,100 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with increased risk for bleeding: <b>Note:</b> For patients with higher-than-average bleeding risk, may administer the same total daily dose in 2 equally divided doses:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-based dosing: <b>SUBQ:</b> 86 anti-Xa units/kg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Fixed dosing: <b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:10em;">40 to 49 kg: 3,800 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">50 to 59 kg: 4,750 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">60 to 69 kg: 5,700 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">70 to 79 kg: 6,650 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">80 to 89 kg: 7,600 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥90 kg: 8,550 anti-Xa units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapeutic anticoagulation (first episode, general recommendations):</i> Optimal duration of therapy is unknown and depends on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preference.</p>
<p style="text-indent:-2em;margin-left:6em;">Provoked deep vein thrombosis: 3 months (provided the provoking risk factor is no longer present) (ACCP [Stevens 2021]).</p>
<p style="text-indent:-2em;margin-left:6em;">Unprovoked deep vein thrombosis or provoked venous thromboembolism with a persistent risk factor: ≥3 months depending on risk of venous thromboembolism (VTE) recurrence and bleeding (ACCP [Stevens 2021]; ISTH [Baglin 2012]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> All patients receiving indefinite therapeutic anticoagulation with no specified stop date should be reassessed at periodic intervals.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb195921-af9f-4db4-a33a-6ead01d04fcd">Hemodialysis, intermittent, anticoagulation of circuit</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent, anticoagulation of circuit: </b>
<b>Note:</b> Administer into arterial line at start of each dialysis session; may give additional dose if session lasts longer than 4 hours; adjust dose during subsequent dialysis sessions to plasma anti-Xa levels of 0.5 to 1 anti-Xa units/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-based dosing: <b>SUBQ:</b> Initial: ~65 anti-Xa units/kg single dose (initial maximum dose: 5,700 anti-Xa units).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing: <b>SUBQ:</b> Initial:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;50 kg: 2,850 anti-Xa units single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">50 to 69 kg: 3,800 anti-Xa units single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥70 kg: 5,700 anti-Xa units single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients at risk of hemorrhage: </i>
<b>Note:</b> Doses may be halved. Administer into arterial line at start of each dialysis session; may give additional smaller dose if session lasts longer than 4 hours; adjust dose during subsequent dialysis sessions to plasma anti-Xa levels of 0.2 to 0.4 anti-Xa units/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: <b>SUBQ:</b> Initial: ~32.5 anti-Xa units/kg single dose (initial maximum dose: 2,850 anti-Xa units).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: <b>SUBQ:</b> Initial:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;50 kg: 1,425 anti-Xa units single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">50 to 69 kg: 1,900 anti-Xa units single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥70 kg: 2,850 anti-Xa units single dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe74019d-6e6e-465a-b87c-36eaf775b1f7">Thromboprophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thromboprophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>General surgery:</i>
<b>SUBQ:</b> Initial: 2,850 anti-Xa units administered 2 to 4 hours preoperatively; Maintenance: 2,850 anti-Xa units once daily. Continue therapy for at least 7 days and until ambulant or no longer at deep vein thrombosis (DVT) risk.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>High-risk medical </i>
<i>patients (respiratory failure and/or respiratory infection and/or cardiac failure):</i>
<b>Note:</b> Continue for length of hospital stay or until patient is fully ambulatory and risk of VTE has diminished (ACCP [Kahn 2012]). Extended prophylaxis beyond acute hospital stay is not routinely recommended (ACCP [Kahn 2012]; Sharma 2012). However, in high-risk COVID-19 patients who are discharged from the hospital, some experts would consider extended prophylaxis with a direct oral anticoagulant (eg, rivaroxaban) (Cuker 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">≤70 kg: <b>SUBQ:</b> 3,800 anti-Xa units once daily during the risk period of thromboembolism.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;70 kg: <b>SUBQ:</b> 5,700 anti-Xa units once daily during the risk period of thromboembolism.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hip replacement surgery:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: <b>SUBQ:</b> Initial: 38 anti-Xa units/kg (maximum dose: 3,800 anti-Xa units) 12 hours before surgery (if benefit outweighs risks) and again 12 hours after surgery, followed by 38 anti-Xa units/kg once daily (maximum dose: 3,800 anti-Xa units/day) up to and including postoperative day 3; on postoperative day 4, begin 57 anti-Xa units/kg once daily (maximum dose: 5,700 anti-Xa units/day).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: <b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:8em;">&lt;50 kg: 1,900 anti-Xa units 12 hours before surgery (if benefit outweighs risks) and again 12 hours after surgery, followed by 1,900 anti-Xa units once daily up to and including postoperative day 3; on postoperative day 4, begin 2,850 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">50 to 69 kg: 2,850 anti-Xa units 12 hours before surgery (if benefit outweighs risks) and again 12 hours after surgery, followed by 2,850 anti-Xa units once daily up to and including postoperative day 3; on postoperative day 4, begin 3,800 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥70 kg: 3,800 anti-Xa units 12 hours before surgery (if benefit outweighs risks) and again 12 hours after surgery, followed by 3,800 anti-Xa units once daily up to and including postoperative day 3; on postoperative day 4, begin 5,700 anti-Xa units once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: Optimal duration of prophylaxis is unknown, but it is usually given for a minimum of 10 to 14 days and can be extended for up to 35 days (ACCP [Falck-Ytter 2012]; Bergqvist 1996; Eikelboom 2001; Pai 2022; Sobieraj 2012); some experts suggest a duration at the higher end of range (eg, 30 days) (Pai 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning between anticoagulants</b>
<b>: Note:</b> This provides general guidance on transitioning between anticoagulants; also refer to local protocol for additional detail:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from another anticoagulant to nadroparin:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from therapeutic IV unfractionated heparin infusion to therapeutic-dose nadroparin: Discontinue unfractionated heparin (UFH) and begin nadroparin within 1 hour. <b>Note:</b> If aPTT is not in therapeutic range at the time UFH is discontinued, consult local protocol (Nutescu 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Transitioning from nadroparin to another anticoagulant:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from therapeutic-dose nadroparin to therapeutic IV unfractionated heparin infusion: Start IV UFH (rate based on indication) 1 to 2 hours before the next dose of nadroparin would have been due. <b>Note:</b>
<b>Omit</b> IV UFH loading dose (Nutescu 2007).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from prophylactic nadroparin to therapeutic IV unfractionated heparin: UFH should be started without delay. A UFH bolus/loading dose may be used if indicated.</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from therapeutic-dose nadroparin to warfarin: Start warfarin and continue nadroparin until INR is within therapeutic range (Wittkowsky 2018). <b>Note:</b> Overlap nadroparin with warfarin until INR is ≥2 for at least 2 measurements taken ~24 hours apart (duration of overlap is ~5 days) (ACCP [Ageno 2012]).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from therapeutic-dose nadroparin to a direct oral anticoagulant: Start direct oral anticoagulant within 2 hours prior to the next scheduled dose of nadroparin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991261"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 to &lt;50 mL/minute: Decrease dose by 25% to 33%. Some have suggested that no dose adjustment is needed when used for prophylaxis; one small clinical trial found no change in peak anti-Xa activity after 5 days of nadroparin at prophylactic doses (Atiq 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:4em;">Thromboprophylaxis: Reduce dose by 25% to 33%.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of acute coronary syndromes or deep vein thrombosis: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>
<div class="block doha drugH1Div" id="F50988544"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doo drugH1Div" id="F27749650"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis treatment:</b> Some experts do not recommend a fixed upper dose limit (Nutescu 2009). Consider anti-factor Xa monitoring to ensure a therapeutic dose (ACCP [Garcia 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thromboprophylaxis:</b> In patients with BMI ≥40 kg/m<sup>2</sup>, increasing dose by 30% may be appropriate for some indications (Nutescu 2009).</p></div>
<div class="block doe drugH1Div" id="F3062283"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing; use with caution (increased risk of bleeding in older patients). Close monitoring necessary, especially in patients with low body weight (ie, &lt;45 kg) or predisposed to renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Thromboprophylaxis in high-risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure), immobilized due to acute illness or in ICU: Consider dose reduction to 2,850 anti-Xa units once daily during the risk period of thromboembolism.</p></div>
<div class="block adr drugH1Div" id="F198996"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Calcinosis (injection site), hypoaldosteronism</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism</p>
<p style="text-indent:-2em;margin-left:4em;">Hematological &amp; oncologic: Eosinophilia, hemorrhage (including intracranial hemorrhage, major hemorrhage, retroperitoneal hemorrhage), thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including hematoma at injection site)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin reaction (Schultinge 2013), cutaneous calcification (Nuno-Gonzalez 2011, Seront 2016), erythema of skin, pruritus, skin necrosis (Pérez 2016, Malinauskiene 2022), skin rash, urticaria (Chen 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematoma (Balbay 2004), heparin-induced thrombocytopenia (Malinauskiene 2022, Mumoli 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (Leo 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, migraine</p></div>
<div class="block coi drugH1Div" id="F199011"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to nadroparin, any component of the formulation, or to other low molecular weight heparins and/or heparin; acute infective endocarditis; active bleeding or increased risk of hemorrhage (hemostasis disorder); history of confirmed or suspected immunologically mediated heparin-induced thrombocytopenia (HIT) (delayed-onset severe thrombocytopenia) or positive in vitro test for antiplatelet antibodies in the presence of nadroparin; major blood clotting disorders; hemorrhagic tendency or other conditions involving increase risk of bleeding; organic lesions likely to bleed (active peptic ulceration); hemorrhagic cerebrovascular event; severe uncontrolled hypertension; diabetic or hemorrhagic retinopathy; injuries to or operations on the CNS, eyes, or ears; severe renal insufficiency (creatinine clearance &lt;30 mL/minute when used for treatment); concomitant use of spinal/epidural anesthesia with repeated high-dose nadroparin (eg, 171 anti-Xa units/kg/day).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Use of nadroparin in patients with current HIT or HIT with thrombosis is <b>not</b> recommended and considered contraindicated due to high cross-reactivity to heparin-platelet factor-4 antibody (ACCP [Guyatt 2012]; Warkentin 1999).</p></div>
<div class="block war drugH1Div" id="F198994"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Bleeding may occur at any site during therapy. Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; hemorrhagic stroke; use shortly after brain, spinal, or ophthalmology surgery; in patients treated concomitantly with other drugs known to cause bleeding (eg, platelet inhibitors); recent GI bleeding or ulceration; vascular disorder of the chorio-retina; thrombocytopenia or platelet defects; severe liver disease; hypertensive or diabetic retinopathy; in patients undergoing invasive procedures; and in older patients. Discontinue if bleeding occurs. Protamine infusion may be necessary for serious bleeding (consult Protamine monograph for dosing recommendations).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous necrosis: Cutaneous necrosis preceded by purpura or infiltrated or painful erythematous blotches has been reported rarely; discontinue treatment immediately if suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia possibly by suppressing aldosterone production. Most commonly occurs in patients with risk factors for the development of hyperkalemia (eg, renal dysfunction, concomitant use of potassium-sparing diuretics or potassium supplements, hematoma in body tissues).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Cases of thrombocytopenia including thrombocytopenia with thrombosis have occurred. Use with caution in patients with history of thrombocytopenia (drug-induced or congenital) or platelet defects; monitor platelet count closely. Use is contraindicated in patients with a history of confirmed or suspected heparin-induced thrombocytopenia (HIT) or positive in vitro test for antiplatelet antibodies in the presence of nadroparin. Discontinue therapy and consider alternative treatment if platelets are &lt;100,000/mm<sup>3</sup> and/or thrombosis develops.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe arterial hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in patients with history of GI ulceration; contraindicated in patients with active peptic ulceration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (has not been studied); patients with hepatic failure are at an increased risk of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prosthetic heart valves: Prosthetic valve thrombosis has been reported in patients receiving thromboprophylaxis therapy with low-molecular-weight heparins (LMWHs).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; primarily renally excreted. Dose reductions may be required. Use is contraindicated in severe renal impairment when treating thromboembolic disorders, unstable angina, and non-ST-elevation myocardial infarction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: There is no consensus for adjusting/correcting the weight-based dosage of LMWH for patients who are morbidly obese (BMI ≥40 kg/m<sup>2</sup>). The American College of Chest Physicians Practice Guidelines suggest consulting with a pharmacist regarding dosing in bariatric surgery patients and other obese patients who may require higher doses of LMWH (Gould 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older patients: Use with caution in older patients; dosage reduction may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Elective surgery/procedure: In patients receiving bridging anticoagulation with therapeutic dose nadroparin, the last dose should be administered ~24 hours prior to the surgery/procedure; reinitiate therapy ≥24 hours after the surgery/procedure when bleeding risk is acceptable (ACCP [Douketis 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Packaging (needle cover of prefilled syringe) may contain natural latex rubber.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do <b>not</b> administer IM.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other LMWHs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Knee surgery: Risk of bleeding may be increased in patients undergoing knee surgery and receiving LMWHs. Consider risk versus benefit in this population.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuraxial anesthesia: Epidural or spinal hematomas, including subsequent long-term or permanent paralysis, may occur in patients anticoagulated with LMWH or heparinoids who are receiving neuraxial anesthesia (epidural or spinal anesthesia) or undergoing spinal puncture. Consider risk versus benefit prior to spinal procedures; risk is increased by concomitant agents which may alter hemostasis, the use of indwelling epidural catheters, a history of spinal deformity or spinal surgery, or a history of traumatic or repeated epidural or spinal punctures. Avoid lumbar puncture or spinal or epidural anesthesia for 12 hours following the last nadroparin prophylactic dose or 24 hours following the last nadroparin treatment dose. The timing of subsequent nadroparin doses following catheter removal should be based on careful risk assessment for thrombosis and bleeding. Longer intervals should be considered for patients with renal impairment (doubling the timing of catheter removal). Observe patient closely for bleeding and signs and symptoms of neurological impairment if therapy is administered. If spinal hematoma is suspected, diagnose and treat immediately; spinal cord decompression may be considered although it may not prevent or reverse neurological sequelae.</p></div>
<div class="block prod-avail drugH1Div" id="F11234097"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F52935268"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52867624"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fraxiparine: 2850 units/0.3 mL (0.3 mL); 3800 units/0.4 mL (0.4 mL); 5700 units/0.6 mL (0.6 mL); 9500 units/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fraxiparine Forte: 11,400 units/0.6 mL (0.6 mL); 15,200 units/0.8 mL (0.8 mL); 19,000 units/mL (1 mL)</p></div>
<div class="block adm drugH1Div" id="F199008"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">SubQ: Administer by SubQ injection into anterolateral abdominal wall with subsequent doses to be administered alternately on right and left side of abdominal wall. The thigh may also be used as an alternative site. Do <b>not</b> administer intramuscularly.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: May be administered IV only as initial bolus dose for acute coronary syndromes (unstable angina and NSTEMI [ie, non-Q-wave myocardial infarction]).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Inject into arterial line at start of dialysis session.</p></div>
<div class="block use drugH1Div" id="F199007"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Fraxiparine:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute coronary syndromes:</b> Treatment of unstable angina and non-ST-elevation myocardial infarction myocardial infarction (MI) (ie, non-Q wave MI).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Deep vein thrombosis: </b>Treatment of deep vein thrombosis (DVT). <b>Note:</b> In patients with venous thromboembolism (ie, DVT or pulmonary embolism [PE]) and <i>without</i> cancer, oral anticoagulants are preferred over low-molecular-weight heparin (LMWH) (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent, anticoagulation of circuit: </b>Prevention of clotting during hemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Thromboprophylaxis:</b> Prophylaxis of thromboembolic disorders (particularly DVT and PE) in general and orthopedic surgery, high-risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) immobilized due to acute illness or hospitalized in ICU.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Fraxiparine Forte: </b>Treatment of DVT.</p></div>
<div class="block mst drugH1Div" id="F199064"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299734"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F198998"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithrombin: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with other anticoagulants prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: Heparins (Low Molecular Weight) may increase the serum concentration of Palifermin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54201372"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients undergoing assisted reproduction therapy (ART) may be at increased risk for thrombosis. Venous thromboembolism prophylaxis is not routinely recommended for patients undergoing ART; however, prophylactic doses of low-molecular-weight heparin (LMWH) are recommended for patients who develop severe ovarian hyperstimulation syndrome (ACCP [Bates 2012]; ASH [Bates 2018]; SOGC [Shmorgun 2017]). In addition, prophylactic doses of LMWH are recommended in patients undergoing ART who have a positive antiphospholipid antibody test but are not diagnosed with antiphospholipid syndrome (APS), as well as patients diagnosed with obstetric APS. Therapeutic doses of LMWH are recommended in patients undergoing ART diagnosed with thrombotic APS (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F199014"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Low-molecular-weight heparin (LMWH) does not cross the placenta (ACOG 2018).</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of fetal bleeding or teratogenic effects have not been reported (ACCP [Bates 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of LMWH may be altered; dosing adjustment may be required. Prophylactic doses of LMWH may also need to be modified in pregnant patients at extremes of body weight (ACOG 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Prosthetic valve thrombosis has been reported in patients receiving thromboprophylaxis therapy with LMWHs; pregnant patients may be at increased risk.</p>
<p style="text-indent:0em;margin-top:2em;">The risk of venous thromboembolism (VTE) is increased in pregnant patients, especially during the third trimester and first week postpartum. LMWH is recommended over unfractionated heparin for the treatment of acute VTE in pregnant patients. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant patients with certain risk factors (eg, homozygous factor V Leiden, antiphospholipid antibody syndrome with ≥3 previous pregnancy losses) (ACCP [Bates 2012]; ACOG 2018; ASH [Bates 2018]; ESC [Regitz-Zagrosek 2018]). LMWH may also be considered for VTE prophylaxis in pregnant patients with COVID-19 (NIH 2023). Consult current recommendations for appropriate use in pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">LMWH may be used prior to cesarean delivery in patients with additional risk factors for developing VTE. Risk factors may include a personal history of deep vein thrombosis or pulmonary embolism, inherited thrombophilia, or patients with class III obesity (SMFM [Pacheco 2020]).</p></div>
<div class="block brc drugH1Div" id="F14081018"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if nadroparin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Small amounts of another low-molecular-weight heparin (LMWH) have been detected in breast milk; however, because they have a low oral bioavailability, LMWHs are unlikely to cause adverse events in a breastfeeding infant. Breastfeeding is not recommended by the manufacturer; however, LMWH is considered compatible with breastfeeding (ACCP [Bates 2012]; ACOG 2018; ASH [Bates 2018]).</p></div>
<div class="block mop drugH1Div" id="F199003"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Platelet counts (at baseline and then twice weekly during therapy), bleeding complications including stool occult blood tests, hemoglobin, antifactor Xa levels (recommended to obtain levels 4 hours postdose); renal and hepatic function; potassium in patients at risk for hyperkalemia; signs/symptoms of neurological impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">When used for anticoagulation during hemodialysis, carefully monitor patients for signs of bleeding or clotting in the dialysis session.</p></div>
<div class="block rer drugH1Div" id="F14081019"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Anti-Xa level target (measured 4 hours after administration): Treatment of venous thromboembolism (Garcia 2012):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Once-daily dosing:</i> 1.3 Anti-Xa units/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Twice-daily dosing:</i> 0.6 to 1 Anti-Xa units/mL.</p></div>
<div class="block pha drugH1Div" id="F198993"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nadroparin is a low molecular weight heparin (LMWH) (average molecular weight is ~4,300 daltons, distributed as 2,000 to 8,000 daltons [75% to 85%]) that binds antithrombin III, enhancing the inhibition of several clotting factors, particularly factor Xa. Nadroparin anti-Xa activity (85 to 110 units/mg) is greater than anti-IIa activity (~27 units/mg) and it has a higher ratio of antifactor Xa to antifactor IIa activity compared to unfractionated heparin. LMWHs have a small effect on the activated partial thromboplastin time.</p></div>
<div class="block phk drugH1Div" id="F199010"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>Note:</b> Values reflective of anti-Xa activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Anti-Xa activity: ≥18 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.59 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: ~98%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~3.5 hours (prolonged in renal impairment)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: SubQ: 3 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily)</p></div>
<div class="block phksp drugH1Div" id="F51159709"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased. In patients with moderate impairment (CrCl 36 to 43 mL/minute), mean AUC and half-life increased 52% and 39% respectively; in severe impairment (CrCl 10 to 20 mL/minute), mean AUC and half-life increased 95% and 112% respectively. Patients with CrCl &lt;10 mL/minute receiving hemodialysis had mean increases in AUC and half-life of 62% and 65% respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Mean anti-Xa peak and total exposure increased 22% and 45% respectively when compared to younger subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F199015"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparina | Fraxiparina tx</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine Multidose | Fraxodi | Na sai chang</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine Tx</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine forte</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparin | Fraxiparina | Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine Tx</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparina | Fraxiparina forte</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi | Nadrohep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparina | Fraxodi | Seledie | Seleparina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Fraxodi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Seleparina</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine-f</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Finardan | Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine forte | Fraxodi</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine Tx</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine forte</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi | Nadroparine</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine forte</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxiparine forte</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Fraxodi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine | Nadroparin pharmex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fraxiparine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22315269">
<a name="22315269"></a>Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(suppl 2):e44S-e88S. doi:10.1378/chest.11-2292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315269/pubmed" id="22315269" target="_blank">22315269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939938">
<a name="29939938"></a>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 196: thromboembolism in pregnancy. <i>Obstet Gynecol.</i> 2018;132(1):e1-e17. doi:10.1097/AOG.0000000000002706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/29939938/pubmed" id="29939938" target="_blank">29939938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26478547">
<a name="26478547"></a>Atiq F, van den Bemt LA, Leebeek FW, et al. No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency. <i>Neth J Med</i>. 2015;73(8):373-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/26478547/pubmed" id="26478547" target="_blank">26478547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332937">
<a name="22332937"></a>Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2012;10(4):698-702. doi:10.1111/j.1538-7836.2012.04662.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22332937/pubmed" id="22332937" target="_blank">22332937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15106028">
<a name="15106028"></a>Balbay O, Tuzuner T, Arbak P, Orham Z, Erbas M, Aydogan I. Spontaneous leg hematoma in a patient anticoagulated with nadroparin for suspected pulmonary thromboembolism. <i>Swiss Med Wkly</i>. 2004;134(7-8):110-111. doi:10.4414/smw.2004.10474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/15106028/pubmed" id="15106028" target="_blank">15106028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315276">
<a name="22315276"></a>Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):e691S-e736S. doi: 10.1378/chest.11-2300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315276/pubmed" id="22315276" target="_blank">22315276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482767">
<a name="30482767"></a>Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. <i>Blood Adv</i>. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/30482767/pubmed" id="30482767" target="_blank">30482767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8703168">
<a name="8703168"></a>Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. <i>N Engl J Med</i>. 1996;335(10):696-700. doi:10.1056/NEJM199609053351002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/8703168/pubmed" id="8703168" target="_blank">8703168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35463677">
<a name="35463677"></a>Chen T, Lan L, Sun W, et al. Localized and generalized skin adverse drug reactions to nadroparin calcium injection in 6 cases of pregnant women. <i>J Healthc Eng</i>. 2022;2022:5622482. doi:10.1155/2022/5622482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/35463677/pubmed" id="35463677" target="_blank">35463677</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cuker A, Peyvandi F. Coronavirus disease 2019 (COVID-19): hypercoagulability. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9108990">
<a name="9108990"></a>Davis R, Faulds D. Nadroparin Calcium. A Review of Its Pharmacology and Clinical Use in the Prevention and Treatment of Thromboembolic Disorders. <i>Drugs Aging. </i>1997;10(4):299-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/9108990/pubmed" id="9108990" target="_blank">9108990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11454370">
<a name="11454370"></a>Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. <i>Lancet</i>. 2001;358(9275):9-15. doi:10.1016/S0140-6736(00)05249-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/11454370/pubmed" id="11454370" target="_blank">11454370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315265">
<a name="22315265"></a>Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e278S-e325S. doi:10.1378/chest.11-2404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315265/pubmed" id="22315265" target="_blank">22315265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fraxiparine.1">
<a name="Fraxiparine.1"></a>Fraxiparine and Fraxiparine Forte (nadroparin calcium) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315264">
<a name="22315264"></a>Garcia DA, Baglin TP, Weitz JI, et al. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):24-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315264/pubmed" id="22315264" target="_blank">22315264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315263">
<a name="22315263"></a>Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest. </i>2012;141(2):S227-S277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315263/pubmed" id="22315263" target="_blank">22315263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315261">
<a name="22315261"></a>Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e195S-e226S. doi:10.1378/chest.11-2296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315261/pubmed" id="22315261" target="_blank">22315261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31539157">
<a name="31539157"></a>Leo M, Ponziani FR, Nesci A, et al. Low molecular weight heparin as cause of liver injury: case report and literature review. <i>Eur Rev Med Pharmacol Sci</i>. 2019;23(17):7649-7654. doi:10.26355/eurrev_201909_18888<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/31539157/pubmed" id="31539157" target="_blank">31539157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27058796">
<a name="27058796"></a>Linnemann B, Scholz U, Rott H, et al; Working Group in Women's Health of the Society of Thrombosis and Hemostasis. Treatment of pregnancy-associated venous thromboembolism - position paper from the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). <i>Vasa</i>. 2016;45(2):103-118. doi: 10.1024/0301-1526/a000504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/27058796/pubmed" id="27058796" target="_blank">27058796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35079393">
<a name="35079393"></a>Malinauskiene L, Aleksandraviciute L, Kryzauskaite L, Savlan I. Rare complication of nadroparin injections: skin necrosis and heparin-induced thrombocytopenia syndrome. <i>Clin Case Rep</i>. 2022;10(1):e05297. doi:10.1002/ccr3.5297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/35079393/pubmed" id="35079393" target="_blank">35079393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20043330">
<a name="20043330"></a>Mumoli N, Cei M. Heparin-induced thrombocytopenia associated with pulmonary embolism. <i>Clin Cardiol</i>. 2010;33(2):E65-E67. doi:10.1002/clc.20546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/20043330/pubmed" id="20043330" target="_blank">20043330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12456233">
<a name="12456233"></a>Nagge J, Crowther M, and Hirsh J. Is Impaired Renal Function a Contraindication to the Use of Low-Molecular Weight Heparin? <i>Arch Intern Med. </i>2002;162:2605-2609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/12456233/pubmed" id="12456233" target="_blank">12456233</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Institutes of Health. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated April 20, 2023. Accessed May 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28315732">
<a name="28315732"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;70(2):252-289. doi: 10.1016/j.jacc.2017.03.011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/28315732/pubmed" id="28315732" target="_blank">28315732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22136860">
<a name="22136860"></a>Nuno-Gonzalez A, Calzado-Villarreal L, Gutierrez-Pascual M, et al. An unusual adverse effect of nadroparin injections: Calcinosis cutis. <i>Dermatol Online J</i>. 2011;17(11):4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22136860/pubmed" id="22136860" target="_blank">22136860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nutescu.1">
<a name="Nutescu.1"></a>Nutescu EA, Dager W. Heparin, low molecular weight heparin, and fondaparinux. In: Gulseth M, ed. <i>Managing Anticoagulation Patients in the Hospital.</i> Bethesda, MD: American Society of Health-System Pharmacists; 2007:181.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19458109">
<a name="19458109"></a>Nutescu EA, Spinler SA, Wittkowsky A, et al. Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings. <i>Ann Pharmacother.</i> 2009;43(6):1064-1083.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/19458109/pubmed" id="19458109" target="_blank">19458109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32360109">
<a name="32360109"></a>Pacheco LD, Saade G, Metz TD; Society for Maternal-Fetal Medicine (SMFM). Society for Maternal-Fetal Medicine consult series #51: thromboembolism prophylaxis for cesarean delivery. <i>Am J Obstet Gynecol</i>. 2020;223(2):B11-B17. doi:10.1016/j.ajog.2020.04.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/32360109/pubmed" id="32360109" target="_blank">32360109</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pai M, Douketis JD. Prevention of venous thromboembolism in adult orthopedic surgical patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27118752">
<a name="27118752"></a>Pérez DL, Peña-Romero AG, Díaz-González JM, Domínguez-Cherit J. Nadroparin-induced skin necrosis: clinical manifestation of HIT-2 even in the absence of thrombocytopaenia. <i>BMJ Case Rep</i>. 2016;2016:bcr2016215288. doi:10.1136/bcr-2016-215288<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/27118752/pubmed" id="27118752" target="_blank">27118752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24394737">
<a name="24394737"></a>Schultinge L, Knol HM, Kluin-Nelemans HC, Erwich JJ, Meijer K. Incidence of hypersensitivity skin reactions in patients on full-dose low-molecular-weight heparins during pregnancy. <i>Neth J Med</i>. 2013;71(10):518-522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/24394737/pubmed" id="24394737" target="_blank">24394737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27083299">
<a name="27083299"></a>Seront B, Marot L, Demoulin N, Jadoul M, Morelle J. The Case | Subcutaneous abdominal calcified nodules and severe hyperphosphatemia. <i>Kidney Int</i>. 2016;89(5):1171-1172. doi:10.1016/j.kint.2015.10.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/27083299/pubmed" id="27083299" target="_blank">27083299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22863355">
<a name="22863355"></a>Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? <i>J Thromb Haemost</i>. 2012;10(10):2053-2060. doi:10.1111/j.1538-7836.2012.04874.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22863355/pubmed" id="22863355" target="_blank">22863355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29080733">
<a name="29080733"></a>Shmorgun D, Claman P. No-268-the diagnosis and management of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2017;39(11):e479-e486. doi:10.1016/j.jogc.2017.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/29080733/pubmed" id="29080733" target="_blank">29080733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22412039">
<a name="22412039"></a>Sobieraj DM, Lee S, Coleman CI, et al. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. <i>Ann Intern Med.</i> 2012;156(10):720-727. doi:10.7326/0003-4819-156-10-201205150-00423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22412039/pubmed" id="22412039" target="_blank">22412039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10680037">
<a name="10680037"></a>Turpie AG. Can We Differentiate the Low-Molecular-Weight Heparins? <i>Clin Cardiol. </i>2000;23(suppl I):14-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/10680037/pubmed" id="10680037" target="_blank">10680037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10030768">
<a name="10030768"></a>Warkentin TE and Barkin RL. Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia. <i>Pharmacotherapy. </i>1999;19(2):181-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/10030768/pubmed" id="10030768" target="_blank">10030768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wittkowsky.1">
<a name="Wittkowsky.1"></a>Wittkowsky AK. Warfarin. In: Dager WE, Gulseth MP, Nutescu EA, eds. <i>Anticoagulation Therapy: A Clinical Practice Guide.</i> 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018:13-34.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10060 Version 225.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
